From Targeted Oncology:
Newer immunotherapies being used in kidney cancer can help create a dramatic, durable response, but only in a small subset of patients, according to David E. McDermott, MD. Methods of expanding on progress seen in the field of immunotherapy, both in the case of kidney cancer and other tumor types, was the subject of McDermott’s presentation at the PER® European Congress on Immunotherapies in Cancer held in Barcelona. Researchers have been exploring the PD-1/PD-L1 blockade for many years, as immunotherapy agents of this kind have seen successes in melanoma, lung cancer, and more. McDermott called single-agent therapy targeting the PD-1 pathway blockade the new standard of care for patients with renal cell carcinoma (RCC).
Read the full article.
